New Search

If you are not happy with the results below please do another search

Archive for category: Conditions

1

Potential Adverse Drug Events and Drug-Drug Interactions with Medical and Consumer Cannabidiol (CBD) Use.

Authors: Joshua D. Brown, Almut G. Winterstein
Journal of Clinical Medicine, 8 July 2019

Cannabidiol (CBD) is ubiquitous in state-based medical cannabis programs and consumer products for complementary health or recreational use. CBD has intrinsic pharmacologic effects and associated adverse drug events (ADEs) along with the potential for pharmacokinetic and pharm…

2

Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy.

Authors: Alexandra L. Geffrey, Sarah F. Pollack, Patricia L. Bruno, Elizabeth A. Thiele
Epilepsia, August 2015

OBJECTIVE: Under an expanded access investigational new drug (IND) trial, cannabidiol (CBD) is being studied as a possible adjuvant treatment of refractory epilepsy in children. Of the 25 subjects in the trial, 13 were being treated with clobazam (CLB). Because CLB and CBD are…

3

Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

Authors: Antonio Waldo Zuardi
Brazilian Journal of Psychiatry, September 2008

OBJECTIVE: The aim of this review is to describe the historical development of research on cannabidiol. METHOD: This review was carried out on reports drawn from Medline, Web of Science and SciELO. DISCUSSION: After the elucidation of the chemical structure of cannabidiol in 1…

4

Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.

Authors: Giulia S. Porcaria, Cary Fub, Emily D. Doll, Emma G. Carter, Robert P. Carson
Epilepsy & Behavior, March 2018

Medically refractory epilepsy continues to be a challenge worldwide, and despite an increasing number of medical therapies, approximately 1 in 3 patients continues to have seizures. Cannabidiol (CBD), one of many constituents of the Cannabis sativa or marijuana plant, has rece…

5

An Update on Safety and Side Effects of Cannabidiol: A Review of Clinical Data and Relevant Animal Studies.

Authors: Kerstin Iffland, Franjo Grotenhermen
Cannabis and Cannabinoid Research, 1 June 2017

Introduction: This literature survey aims to extend the comprehensive survey performed by Bergamaschi et al. in 2011 on cannabidiol (CBD) safety and side effects. Apart from updating the literature, this article focuses on clinical studies and CBD potential interactions with o…

6

Cannabinoids in treatment-resistant epilepsy: A review.

Authors: Brooke K. O’Connell, David Gloss, Orrin Devinsky
Epilepsy & Behavior, May 2017

Treatment-resistant epilepsy (TRE) affects 30% of epilepsy patients and is associated with severe morbidity and increased mortality. Cannabis-based therapies have been used to treat epilepsy for millennia, but only in the last few years have we begun to collect data from adequ…

7

The case for assessing cannabidiol in epilepsy

Authors: Maria Roberta Cilio, Elizabeth A. Thiele, Orrin Devinsky
Epilepsia, June 2014

Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the ma…